AFT secures Maxigesic(R) IV distribution in Indonesia

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 11 December 2019

AFT secures Maxigesic
®
IV distribution in Indonesia
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has signed an exclusive distribution
agreement for the registration and commercialisation of Maxigesic IV
®
in Indonesia
with the Jakarta-based PT Dankos Farma.
PT Dankos Farma is a subsidiary of Kalbe Farma Tbk., the largest publicly listed
pharmaceutical company in Southeast Asia.

AFT Managing Director Dr Hartley Atkinson, says the agreement kicks off the process
of commercialisation for Maxigesic IV
®
in Indonesia, which has a total analgesic
market worth US$530m.*
“We are pleased to further grow our distributor network and expand the company’s
partnerships for Maxigesic IV
®
in South East Asia. We are looking forward to working
with PT Dankos Farma to make the most of the strong potential we see in Indonesia
for Maxigesic IV
®
”.
AFT and PT Dankos Pharma will shortly file for regulatory approval for Maxigesic IV
®
, a
process that is expected to take around two years to complete. Following registration,
Maxigesic IV
®
will be commercialised through Kalbe Farma’s strong marketing,
branding and distribution expertise.
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

Notes to editors:
Maxigesic IV
®
is an intravenous form (paracetamol 1000 mg and ibuprofen (as
sodium dihydrate) 300 mg) of AFT’s patented Maxigesic pain relief medicine. It has
been developed as a line extension to Maxigesic tablets, for post-operative pain
relief in hospitals where patients cannot take an oral pain relief medicine such as
Maxigesic.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

* Source: Statista, October 2019
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.